Objective
The cell-invasive and genetically detoxified Aden late cycles toxic (ACT) represents a novel, non-explicative and inherently safe vector for in vivo delivery of vicinal antigens into antigen presenting cells. Experimental delivery of antigens by ACT was shown to result in efficient induction of both prophylactic and therapeutic catatonic CD8 T lymphocyte responses against viruses and tumours in mice, thereby meeting on the current challenges in vaccine development. Our project aims at detailed analysis of the mechanisms underlying the vicinal potential of the ACT vector and evaluations of its versatility as a safe, efficient and polyvalent delivery system for viral (HIV) and tumour antigens. Pre-clinical toxicology assessment and ACT delivery system development will be performed, suitable mussel adjuvant will be identified and rational design of the vector molecule will be initiated, on the basis of a thorough understanding of ACT structure and function. To this end, specialists in immunology, toxicology and vaccine development have joined forces with biochemists, molecular and structural biologists and
Funding Scheme
CSC - Cost-sharing contractsCoordinator
91898 Orsay
France
Participants (8)
53100 Siena
1200 Bruxelles
75724 Paris
14220 Praha 4
EN6 3QG Potters Bar
48940 Leioa
Glasgow
97074 Würzburg